DAFTAR PUSTAKA

Bao, B., & Prasad, A.S. (2019). Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC. *Advances in experimental medicine and biology*, *1152*, 311-334. doi: 10.1007/978-3-030-20301-6_17.

Bertucci, A. et al. (2019). Tumor-Targeting, MicroRNA-Silencing Porous Silicon Nanoparticles for Ovarian Cancer Therapy. *ACS Applied Materials & Interfaces*, *11*, 23926-23937. doi: 10.1021/acsami.9b07980.

Bovicelli, A., D'Andrili, G., & Giordano, A. (2011). New players in ovarian cancer. *Journal of Cellular Physiology*, *226*(10), 2500-2504. doi: 10.1002/jcp.22662.

Cai, K.T. et al. (2018). Upregulated miR-203a-3p and its potential molecular mechanism in breast cancer: A study based on bioinformatics analyses and a comprehensive meta-analysis. *Molecular Medicine Reports*, *18*(6), 4994-5008. doi: 10.3892/mmr.2018.9543.

Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. *Nature Reviews Cancer*, *6*(11), 857-866. doi: 10.1038/nrc1997.

Carrillo, C. et al. (2014). Chitosan nanoparticles as non-viral gene delivery systems: Determination of loading efficiency. *Biomedicine & Pharmacotherapy* 68(6), 75-783. doi: 10.1016/j.biopha.2014.07.009.

Chandrasekar, N., Kumar, K. M. M., Balasubramnian, K. S., Karunamurthy. & R. varadharajan. (2013). Facile synthesis of iron oxide, iron-cobalt and zero valent iron nanoparticles and evaluation of their anti microbial activity, free radicle scavenginging activity and antioxidant assay**.** *Digest Journal of Nanomaterials and Biostructures, 8*(2), 765-775. Retrieved from https://chalcogen.ro/765_Narendhar.pdf.

Chendrimada, T.P. et al. (2005). TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature*, *436*(7051), 740-744. doi: 10.1038/nature03868.

Chen, L. et al. (2018). miR-203a-3p promotes colorectal cancer proliferation and migration by targeting PDE4D. *American Journal of Cancer Research*, *8*(12), 2387–2401. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30662799/.

Chen, M.C. et al. (2013). Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. *Advanced Drug Delivery Reviews*, *65*(6), 865-79. doi: 10.1016/j.addr.2012.10.010.

Cheung, R. C. F., Ng, T.B., Wong, J. H., & Chan, W. Y. (2015). Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications. *Marine Drugs*, *13*(8), 5156-5186. doi: 10.3390/md13085156.

Chhabra, A., Fernando, H., Watkins, G., Mansel, R.E., & Jiang, W.G. (2007). Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. *Oncology Reports*, *18*(4), 935-958. doi: 10.3892/or.18.4.953.

Choi, J., Jung, W. H., & Koo, J. S. (2012). Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. *Histology and Histopathology, 27*(11), 1481−1493. doi: 10.14670/HH-27.1481.

Clogston, J. D., & Patri, A. K (2011). Zeta potential measurement. *Methods in Molecular Biology*, *697*, 63-70. doi: 10.1007/978-1-60327-198-16.

Csaba, N., Köping-Höggård, M., & Alonso, M. J. (2009). Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. *International Journal of* Pharmaceutics, *382*(1-2), 205-14. doi: 10.1016/j.ijpharm.2009.07.028

Dai, X. et al. (2015). Breast cancer intrinsic subtype classification, clinical use and future trends. *American Journal of Cancer Research*, *5*(10), 929-2943. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26693050/.

Danaei, M. et al. (2018). Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. *Pharmaceutics, 10*(2), 57. doi: 10.3390/pharmaceutics10020057.

De Carvalho, A. C. et al. (2015). Accuracy of microRNAs as markers for the detection of neck lymph node metastases in patients with head and neck squamous cell carcinoma. *BMC Medicine*, *13*, 108. doi: 10.1186/s12916-015-0350-3.

DeCastro, A. J. et al. (2013). MiR203 mediates subversion of stem cell properties during mammary epithelial differentiation via repression of ΔNP63α and promotes mesenchymal-to-epithelial transition. *Cell Death & Disease, 4(*2), 1-10. doi: 10.1038/cddis.2013.37.

Denizli, M. et al. (2017). Chitosan Nanoparticles for miRNA Delivery. *Methods in Molecular Biology*, *1632*, 219-230. doi: 10.1007/978-1-4939-7138-1_14.

Denli, A.M., Tops, B. B. J., Plasterk, R. H. A., Ketting, R. F., & Hannon, G. J. (2004). Processing of primary micro-RNA s by the Microprocessor complex. Nature, *432*(7014), 235-240. doi: 10.1038/nature03049.

Deng, X. et al. (2014). Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. *Biomaterial*, *35*(14), 4333-4344. doi:10.1016/j.biomaterials.2014.02.00.

Ding, L. et al. (2019). MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer. *Cells*, *8*(12), 1492. doi:10.3390/cells8121492.

Elsawaf, Z., & Sinn, H. (2011). Triple-negative breast cancer: clinical and histological correlations. *Breast Care*, *6*(4), 273–278. doi: 10.1159/000331643.

Feng, Y. et al. (2018). Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes & Disease*, *5*(2), 77-106. doi: 10.1016/j.gendis.2018.05.001.

Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018). Molecular subtypes and local-regional control of breast cancer. *Surgical Oncology Clinics of North* America, *27*(1), 95-120. doi:10.1016/j.soc.2017.08.005.

Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006). Clonogenic assay of cells in vitro. *Nature*, *1*, 2315-2319. doi: 10.1038/nprot.2006.339.

Freitas, J. T., Jozic, I., & Bedogni, B. (2021). Wound Healing Assay for Melanoma Cell Migration. *Methods in Molecular Biology*, *2265*, 65-71. doi: 10.1007/978-1-0716-1205-7_4.

Frixa, T., Donzelli, S., & Blandino, G. (2015). Oncogenic MicroRNAs: Key Players in Malignant Transformation. *Cancers*, *7*(4), 2466–2485. doi: 10.3390/cancers7040904.

Fu, S., Xia, J., & Wu, J. (2016). Functional Chitosan Nanoparticles in Cancer Treatment. *Journal of Biomedical Nanotechnology*, *12*(8), 1585-1603. doi: 10.1166/jbn.2016.2228.

Gan, Q., Wang, T., Cochrane, C., & McCarron. P. (2005). Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. *Colloids and Surfaces B: Biointerfaces*, *44*(2-3), 65-73. doi: 10.1016/j.colsurfb.2005.06.001.

Gocze, K. et al. (2013). Unique MicroRNA Expression Profiles in Cervical Cancer. *Anticancer Research*, *33*(6), 2561-2568. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23749909/.

Gomes, B.C. et al. (2016). Prognostic value of microRNA-203a expression in breast cancer. *Oncology Reports*, *36*(3), 1748-1756. doi: 10.3892/or.2016.4913.

Gottardo, F. et al. (2007). Micro-RNA profiling in kidney and bladder cancers. *Urologic Oncology*, *25*(5), 387-92. doi: 10.1016/j.urolonc.2007.01.019.

Graves, P., & Zeng, Y. (2012). Biogenesis of Mammalian MicroRNAs: A Global View. *Genomics Proteomics Bioinformatics*, *10*, 239-245. doi: 10.1016/j.gpb.2012.06.004.

Gregory, R.I. et al. (2004). The Microprocessor complex mediates the genesis of micro-RNAs. *Nature*, *432*, 235-240. doi: 10.1038/nature03120.

Gaur. S. (2015). Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget*, *6*(30), 29161-29177. doi: 10.18632/oncotarget.4971.

Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. *Nature Reviews Molecular Cell Biology*, *15*, 509–524. doi: 10.1038/nrm3838.

He, S., Zhang, G., Dong, H., Ma, M., & Sun, Q. (2016). miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer. *Onco Targets and Therapy*, *9*, 6203-6210. doi: 10.2147/OTT.S108712.

Hemmatzadeh, M., Mohammadi, H., Jadidi-Niaragh, F., Asghari, F., & Yousefi, M. (2016). The role of oncomirs in the pathogenesis and treatment of breast cancer. *Biomedicine & Pharmacotherapy*, *78*, 129-139. doi: 10.1016/j.biopha.2016.01.026.

Herdiana, Y., Wathoni, N., Shamsuddin, S., & Muchtaridi, M. (2022). Drug release study of the chitosan-based nanoparticles. *Heliyon*, *8*(1), e08674. doi: 10.1016/j.heliyon.2021.e08674.

Huang, M., Khor, E., & Lim, L. Y. (2004). Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. *Pharmaceutical Research*, *21*(2), 344-353. doi: 10.1023/b:pham.0000016249.52831.a5.

Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. *British Journal of Pharmacology*, *162*(6), 1239-1249. doi: 10.1111/j.1476-5381.2010.011.

Huo, W. et al. (2017). miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis. *FEBS Open* Bio, *7*(8), 1085–1091. doi: 10.1002/2211-5463.12248.

Hwang, H.W., Wentzel, E.A., & Mendell, J. T. (2009). Cell-cell contact globally activates microRNA biogenesis. *Proceeding of the National Academy of Sciences of the United Stated of America*, *106*(17), 7016-7021. doi: 10.1073/pnas.0811523106.

Iorio M. V. et al. (2007). MicroRNA Signatures in Human Ovarian Cancer. *Cancer Research*, *67*(18), 8699-8707. doi: 10.1158/0008-5472.CAN-07-1936.

Jézéquel, P. et al. (2015). Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. *Breast Cancer Research*, *17*(43), 1-16. doi: 10.1186/s13058-015-0550-y.

Joseph, E., & Singhvi, G. (2019). Multifunctional nanocrystals for cancer therapy: a potential nanocarrier. *Nanomaterials for Drug Delivery and Therapy*. Romania: Elsevier.

Justus, C. R., Leffler, N., Ruiz-Echevarria, M., & L. V. Yang. (2014). *In Vitro* Cell Migration and Invasion Assays. *Journal of Visualized Experiments*, (88), 51046. doi: 10.3791/51046.

Kang, B. S., Lee, S. E., Lian, C., Cho, C. W., & Park, J. S. (2015). Determination of preparation parameters for albendazole-loaded nanoparticles using chitosan and tripolyphosphate. *Journal of Pharmaceutical Investigation*, *45*, 265-269. doi: 10.1007/s40005-015-0171-6.

Karimi, M. et al. (2013). Evaluation of Chitosan-Tripolyphosphate Nanoparticles as a p- shRNA Delivery Vector: Formulation, Optimization and Cellular Uptake Study. *Journal Nanopharm Drug Delivery*, *1*(3), 266–278. doi:10.1166/jnd.2013.1027.

Katz, D. et al. (2018). Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. *BioTechniques*, *44*(2S), 9-14. doi: 10.2144/000112757.

Kementerian Kesehatan Republik Indonesia. (2016). Panduan Penatalaksanaan Kanker Payudara. *Pedoman Pelayanan Nasional Kedokteran*. Indonesia: KEMENKES RI.

Khan, S., Ayub, H., Khan, T., & Wahid, F. (2019). MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer. *Biochimie*, *167*, 12-24. doi: 10.1016/j.biochi.2019.09.001.

Kharia, A. A., Singhai, A. K., & Varma, R. (2012). Formulation and Evaluation of Polymeric Nanoparticle of an Antiviral Drug of Gastroretention. International *Journal of Pharmaceutical Science and Nanotechnology*, *4*(4), 1557-1559. doi: 10.37285/ijpsn.2011.4.4.6.

Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, *75*(5), 843-853. doi: 10.1016/0092-8674(93)90529-y.

Lee, Y. et al. (2004). MicroRNA genes are transcribed by RNA polymerase II. *The EMBO Journal*, *23*(20), 4051-4060. doi: 10.1038/sj.emboj.7600385.

Lehmann, B. D. et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *The Journal of clinical investigation*, *121*(7), 2750-67. doi: 10.1172/JCI45014.

Lennox, K. A., & Behlke, M. A. (2010). A direct comparison of anti-microRNA oligonucleotide potency. *Pharmaceutical* Research, *27*(9), 1788-1799. doi: 10.1007/s11095-010-0156-0.

Liao, M. et al. (2021). Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. *Journal of Medical Chemistry*, *64*(5), 2382-2418. doi: 10.1021/acs.jmedchem.0c01180.

Lima, R. T., Busacca, S., Almeida, G. M., Fennell, D. A. & Vasconcelos, M. H. (2011). *European Journal of Cancer*, *7*(2), 163-74. doi: 10.1016/j.ejca.2010.11.005.

Liu, H.Y. et al. (2019). MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM. *Journal of Ovarian Research*, *12*, 1-3. doi: 10.1186/s13048-019-0532-2.

Liu, J., Valencia-Sanchez, M. A., Hannon, G. J. & Parker, R. (2005). Micro-RNA-dependent localization of targeted mRNAs to mammalian P-bodies. *Nature Cell Biology*, *7*(7), 719-723. doi: 10.1038/ncb1274.

Liu, J. et al. (2021). Progress of non-coding RNAs in triple-negative breast cancer. *Life Sciences*, *272*, 1-13. doi: 10.1016/j.lfs.2021.119238.

Liu, Z. et al. (2012). MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. *The Journal of Pathology*, *228*(2), 204-215. doi: 10.1002/path.4000.

Loh, J. W., Yeoh, G., Saunders, M., & Lim, L.Y. (2010). Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. *Toxicology and applied pharmacology*, *249*(2), 148-57. doi: 10.1016/j.taap.2010.08.029.

Lu, X., Yu, Y., Liao, F., & Tan, S. (2019). Homo Sapiens Circular RNA 0079993 (hsa_circ_0079993) of the POLR2J4 Gene Acts as an Oncogene in Colorectal Cancer Through the microRNA-203a-3p.1 and CREB1 Axis. *Medical Science*

Monitor: International Medical Journal of Experimental and Clinical Research, *25*, 6872-6883. doi: 10.12659/MSM.916064.

MacFarlane, L. A., & Murphy, P. R. (2010). MicroRNA: Biogenesis, Function and Role in Cancer. *Current Genomics*, *11*(7), 537-561. doi: 10.2174/138920210793175895.

Maiti, B., Kundranda, M. N., Spiro, T.P., & Daw, H. A. (2010). The association of metabolic syndrome with triple-negative breast cancer. *Breast Cancer Research and Treatment*, *121*(2), 479–483. doi: 10.1007/s10549-009-0591-y.

Marotti, J. D., de Abreu, F. B., Wells, W. A., & Tsongalis, G. J. (2017). Triple-Negative Breast Cancer Next-Generation Sequencing for Target Identification. *The American Journal of Pathology*, *187*(10), 2133-2138. doi: 10.1016/j.ajpath.2017.05.018.

Martínez-Torres, A. C. et al. (2018). Chitosan gold nanoparticles induce cell death in HeLa and MCF-7 cells through reactive oxygen species production. *International Journal of Nanomedicine*, *13*, 3235-3250. doi: 10.2147/IJN.S165289.

Masarudin, M. J., Cutts, S. M., Evison, B. J., Phillips, D. R., & Pigram, P. J. (2015). Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [^{14}C]-doxorubicin. *Nanotechnology Science and Applications*, *8*, 67-80. doi: 10.2147/NSA.S91785.

McDonald, M. K., & Ajit, S. K. (2015). MicroRNA Biology and Pain. *Progress in Molecular Biology and Translational* Science, 131, 215–249. doi: 10.1016/bs.pmbts.2014.11.01.

Mehrgou, A., & Akouchekian, M. (2016). The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. *Medical Journal of The Islamic Republic of Iran*, *56*, 1-12. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972064/.

Mendell, J. T., & Olson, E. N. (2012). Micro-RNA in stress signaling and human disease. Cell, *148(*6), 1172-1187. doi: 10.1016/j.cell.2012.02.005

Mohammed, M. A., Syeda, J. T. M., Wasan, K. M., & Wasan, E. K. (2017). An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. *Pharmaceutics*, *9*(4), 53. doi:10.3390/pharmaceutics9040053.

Mohanraj, V. J., & Chen, Y. (2006). Nanoparticles – A Review. *Tropical Journal of Pharmaceutical Research*, *5*(1), 561-573. Retrieved from https://www.ajol.info/index.php/tjpr/article/view/14634.

Muhammad, N., Bhattacharya, S., Steele, R, & Ray, R. B. (2016). Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. *Oncotarget*, *7*(36), 58595-58605. doi: 10.18632/oncotarget.11193.

Nidhin, M., Indumathy, R., Sreeram, K. J., & Nair, B. U. Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. *Bullletin*

of Materials Science, *31*, 93-96. Retrieved from https://link.springer.com/article/10.1007/s12034-008-0016-2.

Nisa, U., Astuti, I., Martien, R., Maulana, D. R., & Ysrafil. (2020). Chitosan Nanoparticle as a Delivery System of miRNA 217 for Suppressing Hepatocellular Carcinoma Progressivity by Targeting AEG-1/P53. *1'st Jendral Soedirman International Medical Conference*, 131-138. doi: 10.5220/0010489001310138.

Nishimura, R., & Arima, N. (2008). Is triple negative a prognostic factor in breast cancer?. *Breast* Cancer, *15*, 303–308. doi: 10.1007/s12282-008-0042-3.

Nguyen, D. D., & Chang, S. (2018). Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs. *International Journal of Molecular Sciences*, *19*, 1-17. doi:10.3390/ijms19010065.

Otoukesh, B., Abbasi, M., Gorgani, H., Farahini, H., Moghtadaei, M., Boddouhi, B., Kaghazian, P., Hosseinzadeh, S. & Alaee, A. (2020). MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma. *Cancer Cell International*, *20*, 254. doi: 10.1186/s12935-020-01342-4.

Pal, S. L., Jana, U, Manna, P. K., Mohanta, G. P., & Manavalan, R. (2011). Nanoparticle: An overview of preparation and characterization. *Journal of Applied Pharmaceutical Science*, *1*(6), 228-234. https://www.japsonline.com/admin/php/uploads/159_pdf.pdf.

Patra, J.K. et al. (2018). Nano based drug delivery systems: recent developments and future prospects. *Journal of Biotechnology*, *16*, 71. doi:10.1186/s12951-018-0392-8.

Peng, Y., & Croce, C. M. (2016). The role of MicroRNAs in human cancer. *Signal Transduction and Targeted Therapy*, *1*, 15004. doi:10.1038/sigtrans.2015.4.

Phipps, A.I. et al. (2011). Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer. *JNCI: Journal of the National Cancer Institute*, *103*(6), 470–477. doi: 10.1093/jnci/djr030.

Piasecka, D., Braun, M., Kordek, R., Sadej, R., & Romanska, H. (2018). MicroRNAs in regulation of triple-negative breast cancer progression. *Journal of Cancer Research and Clinical Oncology*, *144*, 1401-1411. doi.org/10.1007/s00432-018-2689-2.

Pillai, R.S. et al. (2005). Inhibition of translational initiation by Let-7 MicroRNA in human cells. *Science*, *309*(5740), 1573-1576. doi: 10.1126/science.1115079.

Rizkita, K. D., Ysrafil., Martien R., & Astuti, I.m(2021). Chitosan nanoparticles mediated delivery of miR-106b-5p to breast cancer cell lines MCF-7 and T47D. *International Journal of Applied Pharmaceutics*, *13*(1), 129-134. doi: 10.22159/ijap.2021v13i1.39749.

Roi, S. S., & Vadlamudi, R. K. (2012). Role of Estrogen Receptor Signaling in Breast Cancer Metastasis. *International Journal of Breast Cancer*, 2012. doi.org/10.1155/2012/654698.

Ru, P., Steele, R., Hsueh, E. C., & Ray, R. B. (2011). Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. *Genes Cancer*, *2*(7), 720-727. doi: 10.1177/1947601911425832.

Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nature Reviews Drug Discovery*, *16*(3), 203-222. doi: 10.1038/nrd.2016.246.

Santos-Carballal, B. et al. (2015). Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. *Scientific Reports, 5*, 13567. doi: 10.1038/srep13567.

Satriyo, P. B. (2019). MicroRNA Profiling and Potential Treatment of 4AAQB Against Oncomir in Triple Negative Breast Cancer. (Doctoral thesis). Universitas Gadjah Mada, Yogyakarta, Indonesia.

Satriyo, P. B. et al. (2020). Dual Therapeutic Strategy Targeting Tumor Cells and Tumor Microenvironment in Triple-negative Breast Cancer. *Journal of Cancer Research and Practice, 7*, 139-148. doi: 10.4103/JCRP.JCRP_13_20.

Schetter, A.J. et al. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA, 99*(4), 425-36. doi: 10.1001/jama.299.4.425.

Siadati, S., Sharbatdaran, S., Nikbakhsh, N., & Ghaemian N. (2015). Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast. *Iranian Journal of Pathology, 10*(3): 221-226. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539777/.

Sharifi-Rad, J. et al. (2021). Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. *Cancer Cell International*, *21*(1), 318. doi: 10.1186/s12935-021-02025-4.

Sofi, M., Young, M. J., Papamakarios, T., Simpson, E. R., & Clyne, C. D. (2003). Role of CRE-binding protein (CREB) in aromatase expression in breast adipose. *Breast Cancer Research and Treatment*, *79*(3), 399-407. doi: 10.1023/a:1024038632570.

Stockert, J. C., Horobin, R. W., Colombo, L. L., & Blázquez-Castro, A. (2018). Tetrazolium salts and formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling perspectives. *Acta Histochemica, 120*(3), 159-167. doi: 10.1016/j.acthis.2018.02.005.

Suardi, R. B. et al. (2020). The effects of Combination of Mimic miR-155-5p and Antagonist miR-324-5p Encapsulated Chitosan in Ovarian Cancer SKOV3. *Asian Pacific Journal of Cancer Prevention*, *21*(9), 2603-2608. doi: 10.31557/apjcp.2020.21.9.2603.

Sung, H. et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Ca: A Cancer Journal for Clinicians, 71*, 209-249. doi: 10.3322/caac.21660.

Tsai, M. L., Davis, R. H., Bai, S. W., & Chen, W. Y. (2011). The storage stability of chitosan/tripolyphosphate nanoparticles in a phosphate buffer. *Carbohydrate Polymers, 84*(2), 756–761. doi: 10.1016/carbpol.2010.04.040.

Uscanga-Perales, G. I., Santuario-Facio, S. K., & Ortiz-López, R. (2016). Triple negative breast cancer: Deciphering the biology and heterogeneity. *Medicina Universitaria*, *18*(71), 105-114. doi: 10.1016/j.rmu.2016.05.007.

Vyas, A., Saraf, S., & Saraf, S. (2009). Encapsulation of cyclodextrin complexed simvastatin in chitosan nanocarriers: A novel technique for oral delivery. *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, *66*, 251-259. Retrieved from https://link.springer.com/article/10.1007/s10847-009-9605-y.

Wang, C., Zheng, X., Shen, C., & Shi, Y. (2012). MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. *Journal of Experimental & Clinical Cancer Research*, *31*(1), 58. doi: 10.1186/1756-9966-31-58.

Weisman, P. S. et al. (2016). Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. *Modern Pathology*, *29*(5), 476–488. doi: 10.1038/modpathol.2016.39.

Wilcock, P., & Webster, R. M. (2021). The breast cancer drug market. *Nature Reviews Drug Discovery*, *20*(5), 339–340. doi: 10.1038/d41573-021-00018-6.

Yang, Z., & Liu, Z. (2020). The Emerging Role of MicroRNAs in Breast Cancer. *Journal of Oncology*, 2020. doi:10.1155/2020/9160905.

Ysrafil. (2019). Efek sitotoksisitas sediaan nanopartikel kitosan berbasis mikroRNA terhadap kultur sel line kanker ovarium SKOV3. Tesis. Program Studi Magister Ilmu Biomedis, Fakultas Kedokteran, Kesehatan Masyarakat & Keperawatan. Universitas Gadjah Mada. Yogyakarta.

Ysrafil, Y., & Astuti, I. (2022). Chitosan nanoparticle-mediated effect of antimiRNA-324-5p on decreasing the ovarian cancer cell proliferation by regulation of GLI1 expression. *Bioimpacts*, *12*(3), 195-202. doi: 10.34172/bi.2021.22119.

Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007). microRNAs as oncogenes and tumor suppressors. *Developmental Biology*, *302*(1), 1-12. doi: 10.1016/j.ydbio.2006.08.028.